FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On August 14, 2025, we reported on the US FDA approval of brensocatib (BRINSUPRI™) 10 mg and 25 mg tablets as the first treatment for non–cystic fibrosis bronchiectasis (NCFB) in persons aged ≥12 years.

The approval

Brensocatib is a first-in-class, once-daily oral dipeptidyl peptidase 1 (DPP1) inhibitor that targets neutrophil serine proteases, key drivers of airway inflammation in NCFB. The approval was supported by data from the phase 3 ASPEN and phase 2 WILLOW trials, both published in The New England Journal of Medicine.

In ASPEN, annual exacerbation rates were reduced by 21.1% with brensocatib 10 mg and 19.4% with 25 mg compared with placebo. Secondary endpoints showed prolonged time to first exacerbation, a higher proportion of patients remaining exacerbation-free, and less decline in forced expiratory volume in 1 second (FEV₁) at 52 weeks in the 25 mg group. The most common adverse reactions (≥2%) included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension.

WILLOW results demonstrated similar efficacy and safety findings, though gingival and periodontal adverse events were reported more frequently.

Click here for more details.